Biopharmaceutical company Jazz Pharmaceuticals (NASDAQ:JAZZ) is currently evaluating strategic options, including a potential sale, as reported by Bloomberg.
Jazz is also considering a potential split or divestment of its business verticals and has already initiated discussions with advisers to gauge interest. A potential transaction could involve the separation of its oncology and cannabinoid operations.
Crucially, the firm could pop up on the radars of larger healthcare players thanks to its capabilities in neuroscience and oncology. The company offers treatments for epilepsy and sleep disorders and is also developing treatments for hematologic malignancies and solid tumors.
Nearly two years ago, Jazz made a significant acquisition, purchasing GW Pharmaceuticals for nearly $7.2 billion. In comparison, a share price slump of nearly 16% year-to-date has reduced Jazz’s market capitalization to ~$8.34 billion. This corrected valuation, coupled with a steady uptick in Jazz’s revenue over the past three years, may attract potential suitors interested in the company.
What Is the Price Target for Jazz Stock?
Meanwhile, the Street has a Strong Buy consensus rating on Jazz. The average JAZZ price target of $202.75 implies a substantial 53.6% potential upside.
Read full Disclosure
